Press releases
GSK initiates voluntary open offer to increase stake in its publically-listed Consumer Healthcare subsidiary in India
GlaxoSmithKline (“GSK”) (LSE: GSK) today announced a Voluntary Open Offer (the “Offer”) to increase its stake in its publicly-listed Consumer Healthcare subsidiary in India (GlaxoSmithKline Consumer Healthcare Ltd, the “Company”) from 43.2% to up to 75% at a price of INR 3,900 per share.
GSK supports Coronation Festival event at Buckingham Palace Gardens marking 60 years of innovation and excellence
GlaxoSmithKline (GSK) today announced it will be a headline partner at the Coronation Festival, which will take place from the 11th-14th July 2013 to celebrate 60 years of British industry, innovation and excellence and commemorate the 60th anniversary of Her Majesty The Queen’s Coronation.
FDA approves new indication for PROMACTA® (eltrombopag)
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Data published in The Lancet show GlaxoSmithKline’s Synflorix is highly effective at preventing invasive pneumococcal disease
Results from the first randomised controlled European clinical trial of a pneumococcal conjugate vaccine (PCV) to examine impact on invasive pneumococcal disease (IPD) were published today in The Lancet.
GlaxoSmithKline announces vote from FDA advisory committee to recommend approval of H5N1 influenza vaccine candidate.
GlaxoSmithKline plc (GSK) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously 14-0 that the safety and immunogenicity data of the H5N1 adjuvanted influenza vaccine candidate supports its licensure for the active immunisation for the prevention of disease in persons 18 years of age and older who are at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine.
ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults
ViiV Healthcare today announced 24-week data from the VIKING-3 Phase III study evaluating the investigational integrase inhibitor (INI) dolutegravir in HIV-1 infected adults with multiple class antiretroviral (ARV) resistance including resistance to integrase inhibitors (raltegravir and/or elvitegravir).
GSK Responds to Hurricane Sandy Relief Needs
- $330,000 Donated for Community Relief
RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
Results of ongoing Phase III clinical trial announced.
GlaxoSmithKline and XenoPort mutually agree to terminate their collaboration on Horizant
GlaxoSmithKline (GSK) plc announced today that it has reached an agreement with XenoPort, Inc., to terminate their collaboration concerning Horizant® (gabapentin enacarbil) Extended-Release Tablets, for which GSK had commercialisation rights and certain development rights in the United States.
GSK announces FDA Advisory Committee vote in favour of raxibacumab for the treatment of inhalational anthrax infection
GlaxoSmithKline announced today that the Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) voted 16 to 1 in support of the clinical benefit of raxibacumab for the treatment of inhalational anthrax, with one abstention.
